Future of haemophilia outcome assessment: registries are key to optimized treatment.
作者信息
Berntorp E
机构信息
Department of Translational Medicine, Lund University and Centre for Thrombosis and Haemostasis, Skane University Hospital, Malmö, Sweden.
出版信息
J Intern Med. 2016 Jun;279(6):498-501. doi: 10.1111/joim.12504.
PMID:27199237
Abstract
摘要
相似文献
1
Future of haemophilia outcome assessment: registries are key to optimized treatment.血友病结局评估的未来：注册登记是优化治疗的关键。
J Intern Med. 2016 Jun;279(6):498-501. doi: 10.1111/joim.12504.
2
Registry-based outcome assessment in haemophilia: a scoping study to explore the available evidence.基于登记的血友病结局评估：探索现有证据的范围研究。
J Intern Med. 2016 Jun;279(6):502-14. doi: 10.1111/joim.12434. Epub 2016 Mar 21.
3
[Revision consensus hemophilia: treatment and responsibility. Nederlandse Vereniging van Hemophilia Patients].[修订版血友病共识：治疗与责任。荷兰血友病患者协会]
Ned Tijdschr Geneeskd. 1997 Dec 27;141(52):2566-71.
4
Assessment of outcomes.结果评估。
Haemophilia. 2014 May;20 Suppl 4:114-20. doi: 10.1111/hae.12426.
5
[Home treatment in hemophilia].[血友病的家庭治疗]
Wien Klin Wochenschr. 1987 Nov 20;99(22):773-7.
6
Home treatment of haemophilia and Christmas disease: five years' experience.血友病和克里斯马斯病的家庭治疗：五年经验
Br J Haematol. 1977 Sep;37(1):53-66.
7
Recent advances in the management of haemophilia and christmas disease.血友病和克里斯马斯病治疗的最新进展。
Clin Haematol. 1979 Feb;8(1):95-114.
8
How I manage patients with inherited haemophilia A and B and factor inhibitors.我如何管理患有遗传性甲型和乙型血友病以及因子抑制剂的患者。
Br J Haematol. 2018 Feb;180(4):501-510. doi: 10.1111/bjh.15053. Epub 2017 Dec 22.
9
Haemophilia treatment in 2030.2030年的血友病治疗。
Haemophilia. 2016 Jul;22 Suppl 5:15-9. doi: 10.1111/hae.13025.
10
Clinical and biological survey of haemophilia A and B patients infused with French heat-treated concentrates.对输注法国热处理浓缩物的甲型和乙型血友病患者的临床与生物学调查。
Nouv Rev Fr Hematol (1978). 1988;30(4):205-7.
引用本文的文献
1
Exploring the relationship between condition severity and health-related quality of life in people with haemophilia A across Europe: a multivariable analysis of data from the CHESS II study.探讨欧洲血友病 A 患者病情严重程度与健康相关生活质量之间的关系：CHESS II 研究数据的多变量分析。
Health Qual Life Outcomes. 2024 Jul 29;22(1):58. doi: 10.1186/s12955-024-02267-6.
2
Economic and Humanistic Burden of Moderate and Severe Hemophilia A and B in Spain: Real-World Evidence Insights from the CHESS II Study.西班牙中重度甲型和乙型血友病的经济与人文负担：来自CHESS II研究的真实世界证据洞察
J Health Econ Outcomes Res. 2024 May 6;11(1):122-133. doi: 10.36469/001c.92369. eCollection 2024.
3
Prophylaxis therapy with bypassing agents in patients with haemophilia A and inhibitors undergoing surgery: A cost analysis in Spain.在患有血友病A且有抑制剂的患者接受手术时使用旁路制剂进行预防性治疗：西班牙的成本分析。
Eur J Haematol. 2020 Jul;105(1):94-100. doi: 10.1111/ejh.13414. Epub 2020 Apr 16.
4
European principles of inhibitor management in patients with haemophilia.欧洲血友病患者抑制剂管理原则。
Orphanet J Rare Dis. 2018 Apr 27;13(1):66. doi: 10.1186/s13023-018-0800-z.
5
The cost of severe haemophilia in Europe: the CHESS study.欧洲重度血友病的成本：CHESS研究
Orphanet J Rare Dis. 2017 May 31;12(1):106. doi: 10.1186/s13023-017-0660-y.
Zotero 插件